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Summary
Purpose: In epilepsy patients treated with vagus nerve stimulation (VNS), the occur-
rence of end of battery life (EOBL), when the generator will no longer deliver any
stimulation, was investigated with regard to seizure control. EOBL is preceeded by
end of effective stimulation (EOES) when irregular stimulation may occur.
Methods: In 14/78 patients, treated with VNS at Ghent University Hospital, gen-
erators were replaced at different times following EOES or EOBL. We retrospectively
analysed the time of occurrence of EOES and EOBL and seizure control before and
after generator replacement.
Results: EOES or EOBL was indicated by loss of seizure control, decreased perception
of stimulation and recurrence of depression in 3, 3 and 1/14 patient(s), respectively.
In 2 and 1/14 patient(s), EOBL and premature generator failure, respectively, were
detected during routine check-up at the epilepsy clinic. In 4/14 patients, generator
replacement was performed before estimated EOES.
Pre-replacement seizure control could not be regained in 2/14 patients in whom
replacement had been postponed for several months. Estimation of EOES and EOBL
occurrence proved difficult in individual patients.
Conclusion: EOES or EOBL may be indicated by loss of seizure control, decreased or
irregular perception of stimulation by the patient and loss of other VNS-induced
effects. Postponing generator replacement may result into permanent loss of seizure
control. In responders we suggest generator replacement before EOBL. Our results
call for performance of prospective studies in larger patient groups that may
eventually lead to general guidelines on the indication and timing of generator
replacement.
# 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +32 9240 4539; fax: +32 9240 4971.
E-mail address: kristl.vonck@ugent.be (K. Vonck).
1059-1311/$ — see front matter # 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.seizure.2004.11.001
90 K. Vonck et al.Introduction
Vagus nerve stimulation (VNS) is a symptomatic add-
on treatment for patients with medically refractory
epilepsy that reduces seizure frequency with more
than 50% in 30% of patients and is available in
epilepsy centers worldwide since 1997.1—3 Patients
with a more than 50% reduction in seizure frequency
are designated as responders. More than 20,000
patients are currently being treated with VNS for
epilepsy. Recent pilot studies have also shown pro-
mising results in medication resistant depression
and Alzheimer’s disease.4,5
VNS is performed by implanting a pulse generator
(VNS Therapy System, Cyberonics, Houston, Texas,
USA) in a subcutaneous pouch in the left chest area.
The pulse generator is connected to a helical elec-
trode that is wound around the left vagus nerve in
the upper neck. In general, intermittent stimulation
is used with standard stimulation parameters (pulse
width: 500 ms; frequency: 30 Hz; duty cycle: on-
time: 30 s, off-time: 300—600 s). Patients or care-
givers are also supplied with a magnet to administer
additional stimulations by applying it over the
implanted generator, which in a substantial number
of patients interrupts an ongoing seizure, or upcom-
ing seizure in case of an aura.6 VNS has mild stimu-
lation-related side effects such as hoarseness and
voice change that most often occur during the
ramping-up period of the output current and during
the stimulation on-time.1—3
The battery life of the generator depends on the
generator model, the programmed stimulation
parameters and the lead impedance values of the
stimulation electrode (normal values: <1—8 kV).
The generator model 100 was the first model devel-
oped for human use with an expected battery life of
4—8 years. It has been replaced by the smaller
model 101 available since 2001 with an expected
battery life of 8—12 years. Model 102 is the most
recently marketed even smaller device and has an
expected battery life between 6 and 11 years. When
a new battery is required, the whole generator is
replaced to prevent opening the hermetically sealed
titanium case and to avoid contact between body
fluids and generator components with the risk of
inducing a rejection reaction. The electrode is
usually left in place.
Patients who underwent generator replacement
have been mentioned in efficacy and safety
reports.7 In the randomized controlled trials, the
high number of patients who underwent replace-
ment and stayed on the treatment was considered a
reflection of the excellent tolerability as well as
efficacy of the treatment.3 The issue of generator
replacement and battery life has been addressed inonly a few reports. There is relatively little informa-
tion on prediction of battery life in individual
patients and there is no consensus on the indication
for replacement, e.g. in patients with a seizure
reduction of <50% or in non-responders who may
benefit from VNS in a different way such as an
increase in the seizure-free interval, a decrease
in seizure severity or duration or improved mood.
As VNS is considered to be a symptomatic treat-
ment, seizure recurrence or loss of beneficial
effects can be expected when the battery of the
generator expires. In a group of 12 patients, seizure
recurrence after end of service due to battery
expiration was reported.8 Following 18 months of
stimulation, there was a 2-week interval after end
of service before seizure rate returned to pre-VNS
numbers. Tatum et al. described a group of 18
patients who underwent generator replacement
and found that seizure increase or changes in seizure
pattern often indicated battery failure.9
Currently, there are only limited reports or guide-
lines in the literature with regard to the indications
and optimal timing for generator replacement.Methods
Since March 1995, 78 patients have been treated
with VNS in the Reference Center for Refractory
Epilepsy at Ghent University Hospital in Belgium.
All patients had refractory complex partial or gen-
eralized epilepsy and were included in the presur-
gical evaluation program that has been described
previously.10 All patients were shown to be ineligible
for resective surgery and subsequently underwent
implantation with the VNS TherapyTM System (model
100 or model 101). The surgical procedure was
performed under general anaesthesia during a 48-
h admission in the neurosurgery department. During
the implantation procedure the generator circuitry
as well as the lead impedance was tested. The
stimulator was activated 2 weeks postoperatively
at the epilepsy clinic using standard stimulation
parameters (pulse width: 500 ms, frequency:
30 Hz, time on/off: 30 s/600 s) and an initial output
current of 0.25 mA.11 The output current was gra-
dually increased every 2—3 weeks up to patient’s
tolerance or until seizure control was reached.
Patients were provided with a magnet to allow
additional stimulations in case of an aura or in case
of a seizure being observed by a caregiver. When
stable regimens of stimulation were achieved
patients were followed-up at the epilepsy clinic
every 3—4 months.
When end of battery life (EOBL) of the generator
is reached, the pulse generator will no longer deli-
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and telemetric communication with the pulse gen-
erator using the programming wand is no longer
possible. However, before EOBL is reached, there
is a time span when the battery nears depletion. For
the purpose of this study we defined this period as
end of effective stimulation (EOES). In the variable
time period of days to months between EOES and
EOBL, the pulse generator can still be interrogated
but may provide ‘unscheduled’ stimulation as stated
in the manufacturer’s manual.12 The generator
replacement procedure consists of disconnecting
the generator from the electrode, removing it in
its whole and replacing it by a new device that is
reconnected to the electrode. The electrode usually
stays in place. The replacement procedure is gen-
erally performed under local anaesthesia in the
operating theatre and lasts for approximately 1 h.
The generator is accessed through a 4—5 cm
incision subclavicularly in the scar tissue of the first
generator implantation. A subcutaneous area of a
few square centimeters exposing the proximal inser-
tion of the electrode into the generator is carefully
dissected. The generators are generally found to be
surrounded by strong connective tissue. In this way,
a pouch is formed around the stimulator that allows
the device to be explanted easily. The electrodes
are disconnected from the generator using the pro-
vided screwdriver and reconnected to a new device.
Following replacement, according to the manufac-
turer, output current should be increased again
gradually during a ramping-up period starting from
0.25 mA.13
The first generator models (model 100) with
serial number under 10.000 have no specific fea-
tures that allow physicians to anticipate EOES or
EOBL when interrogating the device with the avail-
able programming wand. It is recommended by the
manufacturer that patients should be instructed to
activate the pulse generator manually with the
magnet on a daily basis to test for the presence
of perceptible stimulation. Patients should contact
a physician when the stimulation is no longer
felt.12,13 The physician can then confirm EOBL using
the programming wand.
In generator model 100 with serial numbers above
10.000 as well as in model 101 and model 102, a
built-in feature called the ‘elective replacement
indicator’ (ERI) is available. It provides a warning
period prior to EOBL of the device. The time period
between the ERI warning and the actual EOBL is very
variable depending on the programmed stimulation
parameters and lead impedance and may be very
short, e.g. 1 week. The manufacturer does recom-
mend prompt replacement when the ERI is shown by
the laptop software.13It is unclear however, how soon EOES follows the
ERI warning, or whether the two are synonymous.
Generally, in our patients, at 4 years of follow-up
after the initial implantation date, when EOES or
EOBL could be expected, the frequency of the clinic
visits was intensified to once every 2 months.
In responders (>50% seizure frequency reduction)
replacement was planned immediately following
EOES or EOBL. In non-responders (<50% reduction
in seizure frequency), individual cases were consid-
ered and benefits were discussed with the patients
or caregivers. In some cases seizure frequency was
closely observed during the months following EOBL
without changing AED regimens. In case of a sig-
nificant increase in seizure frequency generator
replacement was planned.
Since October 1999, generator replacements
have been performed in 14/78 patients. We com-
pared the different approaches in these patients
and correlated themwith seizure control before and
after generator replacement.Results
In 14/78 patients treated at Ghent University Hos-
pital generators were replaced. In 13 patients,
replacement followed EOES or EOBL. In one patient,
the generator was replaced prematurely due to
generator failure after 16 months of treatment.
Table 1 shows the individual patient characteristics.
A number of 5/14 patients were reimplanted with
the VNS TherapyTM model 100 with serial numbers
above 10.000 and 9/14 received the VNS TherapyTM
model 101. In two cases, the replacement proce-
dure was performed under general anaesthesia on
the patients’ request. Peri-operative testing of gen-
erator circuitry and lead impedance was performed.
In none of the patients was there an indication for
electrode replacement at the time of the procedure
of the generator replacement as intraoperative
testing of the lead showed acceptable impedance
values below 8 kV. There were no peri-operative
complications. All patients were discharged from
the hospital within 24 h. In 6/14 patients, the output
current was programmed at similar pre-replace-
ment values 1 day postoperatively. In one patient,
an output current of 0.5 mA (versus 2.5 mA pre-
replacement) was programmed 1 day postopera-
tively. In 7/14 patients, output current was gradu-
ally ramped-up during the weeks following the
generator replacement procedure.
Table 1 shows the pre- and post-replacement
efficacy and output currents in each patient.
In three patients (UP, BIV, VA) EOES or EOBL was
indicated by loss of seizure control. Two of these
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Table 1 Patien lacement.
pt Gender A
( fore
CPS/month
after generator
replacement
Output current
before generator
replacement
(mA)
Output current
after generator
replacement
(mA)
UP M 3 4 2.75 2.25
VD F 3 0 2.25 1.25
BIV M 3 0 1.75 1.75
VDC F 2 25 2.5 2.5
SP M 3 2 2.5 2.75
HF M 1 0 2.5 0.5a
BI F 2 0 1.5 1.5a
JA F 3 3 2 2a
BJ F 2 45 3 3
VJC F 4 0 1.5 1.25a
VC M 2 2 2.75 2.5a
DKE F 1 6 2.25 2.25a
DK F 2 60 1.75 1.75a
VA F 2 4 2 2
pt: patient; CPS: c ion; SPS: simple partial seizures.
a Stimulation ret characteristics, VNS efficacy and stimulation parameters before and after generator rep
ge
years)
Seizure
duration
(years)
Follow-up
(months)
History Seizure
type
CPS/month
before VNS
CPS/month
after VNS be
generator
replacement
3 22 101 Febrile seizures,
head trauma
CPS + SG 8 0
0 4 101 Head trauma CPS  SG/SPS 3 0
5 12 95 Head trauma CPS  SG 4 0
9 18 94 Encephalitis CPS  SG 40 25
0 18 88 Premature birth,
callosotomy
CPS  SG/SPS 4 2
9 18 88 Febrile seizures CPS + SG 4 <1
1 18 81 Febrile seizures,
head trauma
CPS  SG/SPS 4 0
1 9 78 Febrile seizures CPS  SG 16 3
4 23 76 Febrile seizures,
encephalitis
CPS  SG 35 25
3 35 69 Meningitis with
right frontal
brain abcess
CPS + SG 2 0
0 6 65 Meningitis,
head trauma
CPS 4 2
2 5 60 None CPS  SG 12 6
8 26 48 Lennox—Gastaut
syndrome
CPS  SG 150 60
2 16 43 Surgery for left
temp lesion
CPS 10 4
omplex partial seizures; VNS: vagus nerve stimulation; mA: milliamperes; SG: secondary generalisat
initiated 1 day postoperatively.
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dom.
Exactly 4 years following initial implantation,
patient UP reported the occasional recurrence of
epigastric auras and the feeling that a stimulation
train was initiated but abruptly stopped after a few
seconds. At that time, the pulse generator could still
be interrogated for three more days before EOBL
occurred. Replacement of the generator was post-
poned for 6 months after EOBL due to financial
problems at a time when VNS was not yet reim-
bursed in Belgium. Two months after EOBL, the
patient had a generalized tonic clonic seizure
(GTCS) and seizure frequency increased up to
2 GTCS per month over a time period of 6 months.
Eventually, a public charity provided a grant and the
generator was replaced. Output current was gradu-
ally increased until 2.75 mA but seizure control
could not be regained. Moreover, the patient could
not tolerate this original output current due to neck
muscle pain especially during night time. Output
current was reduced to 2.25 mA which resulted in
relief of the side effects. Seizure frequency further
increased to 4 GTCS per month and in the meantime
the patient was admitted for an episode of convul-
sive status epilepticus. Topiramate and levetirace-
tam were added to his drug regimen without
achieving any improvement in seizure frequency
or severity at the time of this analysis.
In patient BIV, family members had noticed short-
lasting and infrequent break-through episodes of
loss of awareness and asked whether this could be
due to EOES. This was exactly 5 years following
initial implantation. The generator could still be
interrogated. Two months later, EOBL was reached.
When reimbursement was granted 3 weeks later,
replacement was performed. Postoperatively one
more CPS was reported. Output current was reini-
tiated at 1.75 mA over a time period of several
weeks without any CPS or VNS-related side effects
occurring.
Patient VA noticed an increase in CPS from 4/
month to 7/month after 2 years and 10 months of
treatment with VNS on rapid cycling for 2 years. MRI
was planned to investigate the status of the intra-
cranial astrocytoma. Before this procedure was
performed, the generator was interrogated at the
epilepsy clinic and indicated EOBL. Two months
earlier, the generator had been interrogated nor-
mally. MRI showed no changes in the intracranial
lesion. The generator was replaced 1 month later.
After ramping-up to previous output current, sei-
zure control was regained.
In two patients (VDC, BJ) with a <50% reduction
in seizure frequency, generator replacement was
postponed following EOBL detection at the epilepsyclinic. During further follow-up seizure frequency
and severity increased and both patients underwent
replacement of the generator. In patient VDC sei-
zure frequency increased to prestimulation fre-
quency over 4—6 months. Levetiracetam was tried
without success. After 12 months, generator repla-
cement was performed and a reduction of seizure
frequency was reached after several weeks to
25 CPS/month on a stimulation parameter scheme
similar to the one before replacement. In patient
BJ, seizure frequency and severity (recurrence of
secondary generalized convulsions) significantly
increased up to 45 seizures per month over 2 months
time compared to 25 seizures before replacement of
the generator. Following reimplantation 1 month
later, output current was increased over several
weeks up to 3 mA without improvement in clinical
efficacy at follow-up 17 months later.
In one patient, recurrence of a depressive epi-
sode indicated EOBL. Patient VDwas free of complex
partial seizures (CPS) but still had simple partial
motor seizures (SPS) of the left hand. The patient
had last visited the epilepsy clinic 5 years following
initial implantation when pulse generator commu-
nication was still possible. She was then lost in
follow-up for a period of 10 months. Due to the
recurrence of a major depressive episode she was
admitted to a psychiatric hospital and treated with
antidepressant medication. CPS had not reoccurred
nor had the frequency of SPS increased. Pulse gen-
erator interrogation at this time revealed EOBL.
Generator replacement was performed 4 weeks
later and output current gradually increased. The
patient was much more sensitive than before
(throat ache and hoarseness) to the stimulation side
effects, and it took 3 months before an output of
1.25 mA could be reached. In themeantime, she had
recovered from her depression and antidepressant
medication was tapered. The patient remains free
of CPS.
In the remaining eight patients, the generator
replacement period was covered without changes in
seizure frequency. In three patients, a decrease of
stimulation perception indicated EOES. In patient
BI, this occurred 5 years after initial implantation.
Telemetric communication with the generator was
still possible indicating EOES. The generator was
replaced after a few days. No change in seizure
control occurred and output current could be reini-
tiated at 1.5 mA during the postoperative day. In
two patients (SP, HF), the generators could no longer
be interrogated indicating EOBL. In both patients,
the generators had been interrogated normally 2
months before.
In patient SP, initial implantation was performed
3 years and 11 months earlier; in patient HF 6 years
94 K. Vonck et al.earlier. Both patients were reimplanted 1 month
following EOBL. In SP seizure control was main-
tained and output current reinitiated over several
weeks. Patient HF had a 90% reduction in seizure
frequency with the first generator and was put on
0.5 mA the day following the replacement opera-
tion. Since that day and for about 15 months, he has
remained seizure-free. So far, output current has
not been further increased.
In four responders (JA, VJC, VC, DKE), generator
replacement was performed before any signs of
EOES were present. Factors taken into account were
the time of service after initial implantation, lead
impedance values, programmed stimulation para-
meters, use of magnet and estimated battery life
based on the tables in the Physician’s Manual.12
Generator replacement was performed after 72,
63, 61 and 59 months of follow-up, respectively.
Table 2 gives an overview of the time periods and
seizure frequency evolution during treatment with
the initial generator and following replacement of
the generator. It also shows the estimated duration
without stimulation before generator replacement
and the time to recurrence of seizures during this
interval.Discussion
Over the past decade, it has become clear that VNS
is an efficacious treatment in a substantial number
of patients with refractory epilepsy who are left
with few therapeutic alternatives if surgery is not an
option or has not been successful. VNS is an add-on
treatment in patients treated with one or more
antiepileptic drugs. The precise mechanism of
action of VNS in suppressing seizures remains to
be elucidated.14 Some hypotheses such as VNS-
related changes in neurotransmitter release and
thalamic cerebral blood flow have been postu-
lated.15,16 VNS is generally regarded as a sympto-
matic treatment. Increase in clinical efficacy with
longer follow-up has been demonstrated.2,3 This
may be due to VNS-related long-term changes in
the central nervous system as shown by PET and
SPECT studies and may reflect a central modulatory
effect of VNS rather than a purely seizure suppres-
sing effect.17,18
There are indications that seizure frequency may
suddenly increase even during a short period of
interruption of stimulation for the purpose of per-
forming magnetic resonance imaging.19 One report
in the literature describes increased seizure fre-
quency 2 weeks following EOBL.8
All these facts imply that when EOES or EOBL is
reached, the decision as to whether and when thegenerator needs replacement has to be considered
in light of the achieved clinical efficacy with the
initial device. Until now, no specific guidelines are
available for this crucial decision in the ongoing and
strongly individualized treatment that has some-
times taken the treating physicians years to estab-
lish.
In the first patients treatedwith VNS and included
in the EO1 and EO2 open trials, two interesting facts
occurred that may help to document unanswered
questions with regards to this issue.20 First, the
design of the study consisted of alternating 4—8
weeks stimulation periods with 4 weeks control
periods during which stimulation was interrupted.
Secondly, in 9 of the first 10 patients, breakage of
the wires of the electrode occurred resulting in
unexpected interruption of stimulation. Uthman
et al. describe five patients who had electrode
breaks after 10—20 weeks of implantation.21 In
three responders, seizure rate had gradually
recurred to baseline. In two patients, seizure con-
trol was regained within 8 weeks after repair of the
electrode. In one patient, a seizure reduction of 32%
had been achieved 4 weeks following the repair but
no further follow-up was not reported. In one non-
responder, who did report decreased seizure sever-
ity and duration, this effect was reported to be
regained after electrode repair and an additional
30% seizure reduction occurred 8 weeks later. It is
not described in detail but the statement suggests
that the effect on seizure severity and duration had
also been lost following electrode break. In 1993, in
a follow-up report, Uthman et al. describes a case
report that illustrates the time relationship
between stimulation periods, control periods with-
out stimulation, electrode breaks, battery deple-
tion and seizure outcome.20 In a patient with >50%
seizure frequency reduction, control periods were
characterised by a doubling of seizure frequency.
Following the lead break, seizure frequency
returned to baseline after 4—8 weeks. Following
repair, seizure control was regained although it is
not clear over what time period this happened.
After this, the battery depleted after 1 year of
service. Erroneous continuous stimulation at 10 Hz
occurred during 2 weeks. The patient restarted
having SPS and 3 weeks later there was a dramatic
increase in CPS. After the generator was replaced,
seizure control was regained.
Although our patient group is small, it is surpris-
ing that two patients, of whom one was a clear
responder, have not regained seizure control follow-
ing generator replacement. Our data suggest that a
longer time span without stimulation may be asso-
ciated with an increased risk of not regaining seizure
control. Even if VNS provokes long-term changes, it
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Table 2 Time periods and changes in seizure frequency with the first generator, following replacement of the generator and during the time period without VNS.
Patient Time until initial
improvement with
first generator
(months)
Time until stable
seizure frequency
with first generator
(months)
Time until
generator
replacement
(months)
Follow-up after
generator
replacement
(months)
Estimated duration
without VNS before
generator replacement
(months)
Change in seizure
frequency during
time without VNS
Estimated time
until change in
seizure frequency
during time period
without VNS (months)
UP 3 2a 54 41 6 Increase 2
VD 1.5 1.5 71 10 1 No —
BIV 1a 1a 63 26 1 Increase Unknown
VDC 5 7 74 14 12 Increase 4
SP 6 1 48 34 1—3 No —
HF 1 16 73 9 1—3 No —
BI 1a 1a 60 16 0 No —
JA 6 6 74 4 0 No —
BJ 3 12 59 11 3 Increase 2
VJC <1a <1a 63 6 0 No —
VC 3 6 61 4 0 No —
DKE 6 12 59 1 0 No —
DK 3 14 16 32 Unknown No —
VA 10 12 35 8 2 Increase 1
a Seizure free.
96 K. Vonck et al.cannot be considered a curative treatment. There
seems to be a certain safety margin during which
breakthrough auras and infrequent seizures occur.
This is probably due to the fact that during EOES,
stimulation is not stopped abruptly but rather gra-
dually in contrast to the situation where the gen-
erator is suddenly put in the off-mode, e.g. for the
purpose of performing MRI. Apart from the fact that
seizure control is lost, it is currently unclear why it
cannot be regained after reinitiation of VNS. Since
follow-up time after generator replacement in our
patients clearly exceeds the time interval to initial
response to VNS with the first generator, it seems
unlikely that seizure control will be regained after
longer follow-up. One similar case was reported by
Ben-Menachem et al.2 In a patient with primary
generalized epilepsy who had a >75% decrease in
seizures with VNS, the battery expired and was
replaced 2 months later. During that time and the
following weeks, increased generalized tonic sei-
zures resulted in status epilepticus and eventually
death. Analogous problems arise in medical therapy.
It is well known that in individual patients previously
successful antiepileptic treatment does not guaran-
tee efficacy in a second trial later during life.
Only controlled studies can clarify this matter,
as the major confounding factor to be considered
in refractory patients is the natural history of
epilepsy.
In the physician’s manual, the manufacturer pro-
vides approximate battery lives for each available
VNS TherapyTM model. However, the expected time
of EOBL covers a wide span of several years. The
manufacturer also lists different values of battery
life correlated to specific stimulation parameter
combinations and lead impedance values and also
approximate time intervals between EOES or ERI
notification and EOBL. Especially in patients with
high output currents (>2 mA) and/or relatively high
lead impedance values (>3 kV) and/or high duty
cycles, the time between EOES or ERI notification
and EOBL can be very short. There is some evidence
in the literature that high duty cycles with off-times
1.1 min (rapid cycling) may result in a significant
improvement in clinical efficacy in a subgroup of
patients initially resistant to VNS.22 In many
patients, over the years different stimulation para-
meter regimens and duty cycles have been tried, so
estimation of battery life in an individual patient
proves difficult (Table 3). In one of our patients, 2
years of rapid cycle stimulation clearly reduced
battery life to less than 3 years. Moreover, there
is a wide variability in magnet use among patients. It
is unclear to what extent total number of extra
stimulations should be taken into account when
estimating battery life in an individual patient.Lead impedance is clearly an important factor
that has also to be taken into account when battery
life is being considered. Usually, lead impedance
testing is performed perioperatively but it is not
regularly performed during follow-up clinic visits.
However, there are no reports in the literature
suggesting that there is an increase in lead impe-
dance during long-term VNS. Considering the fact
that EOES may be accompanied by the delivery of
unreliable output current, reliable impedance test-
ing at this time may not be possible.
EOES can be suspectedwhen irregular stimulation
is felt by the patient. However, a substantial number
of patients with long follow-up do not feel stimula-
tion on a regular basis or at all. The manufacturer
suggests using the magnet feature to check daily
functioning of the generator. This implies that the
magnet output current be set to a value that causes
a perceptible but not uncomfortable sensation in
the throat. It is not always possible to fine-tune
output current and control side effects in such a
desirable way. Sometimes there is no intermediate
output current between ‘no side effects’ and
‘uncomfortable side effects’ such as throat pain.
Patients who use the magnet primarily in case of an
aura are likely to prefer efficacy without side
effects.
When the magnet is mainly used in case of GTCS,
higher output currents are generally not a problem
during the seizure. When used outside an epileptic
episode, however, this may cause clear side effects.
Moreover, standard on-time for the magnet is
usually 60 s versus 30 s on-time in the automatically
programmed duty cycle. This longer on-time may
prolong discomfort in some patients.
VNS is often used in patients who have both
epilepsy and mental retardation, e.g. Lennox—
Gastaut syndrome. These patients often cannot
report side effects or they produce little sponta-
neous speech so that voice changes cannot be
appreciated when the magnet is applied. In order
to be able to evaluate EOBL, high output currents
would have to be administered causing more ser-
ious and obvious adverse effects such as choking or
coughing.
With regards to generator replacement in respon-
ders (>50% reduction in seizure frequency) and non-
responders (<50% reduction in seizure frequency),
no guidelines are available. From our own experi-
ence, we are of the opinion that it might be ben-
eficial to responders, especially in seizure free
patients, to anticipate EOBL and perform generator
replacement before any signs of EOES have been
reached. The benefit of continued seizure control in
these patients is balanced by the cost of losing
several months of battery life.
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Table 3 Comparison of observed end of effective stimulation and end of battery life and predicted battery life.
Patient Output current
before generator
replacement (mA)a
Magnet output
current (mA)
Use of
magnet
EOES
(years)
EOBL
(years)
Lead
impedanceb
(kV)
Predicted battery lifec (years)
UP 2.25 0 — 4 4 3—5 4.9—4.3 (output current of 2 mA)
VD 2.25 0 — Unknown 5.8d 3—5 4.9—4.3 (output current of 2 mA)
BIV 1.75 1.75 Frequently,
mean: 1/day
5 5.1 3—5 4.9—4.3 (output current of 2 mA)
VDC 2.5a 0 — Unknown 5.1 5—8 4.3—3.8 (output current of 2 mA)
SP 2.5a 2.75 Frequently,
mean: 1/day
Unknown 3.9 3—5 4.9—4.3 (output current of 2 mA)
HF 2.5 0 — Unknown 6 <1 4.9 (output current of 2 mA, lead
impedance of 3 kV)
BI 1.5 0 — 5 Unknown 3—5 4.3—3.8 (output current of 2 mA)
JA 2.5a 2.5 Frequently,
mean: 1/day
Unknown Unknown <1 4.9 (output current of 2 mA, lead
impedance of 3 kV)
BJ 3a 2.25 <1/month Unknown 4.6 <1 4.9 (output current of 2 mA, lead
impedance of 3 kV)
VJC 1.5 0 — Unknown Unknown <1 5.5 (output current of 1 mA, lead
impedance of 3 kV)
VC 2.75 2.75 Seldom Unknown Unknown 3—5 4.9—4.3 (output current of 2 mA)
DKE 2.25 2.5 1/week Unknown Unknown 3—5 4.9—4.3 (output current of 2 mA)
DK 1.75 1.75 Frequently,
mean: 1/day
Unknown Unknown <1 4.9 (output current of 2 mA, lead
impedance of 3 kV)
VA 2e 2.25 Seldom Unknown 34 3—5 4.9—1.9
mA: milliamperes; EOES: end of effective stimulation; EOBL: end of battery life; kV: kiloOhms.
a Other parameters standard with 5% duty cycle (on/off, 30/600 s) except for patients in whom rapid cycle was tried for several months without additional improvement.
b Lead impedance testing performed at 1.0 mA, 500 ms and deducted from physician’s manual model 100—101, Table 10, p. 55.
c Closest possible deduction from listed tables in the physician’s manual model 100—101, Table 14, pp. 64—65 (for model 100 with serial numbers<10.000, values only available for output
currents of 1, 2 mA for lead impedances 3 kV, duty cycles of 10, 30, 50%).
d Approximate value as patient had been lost in follow-up for 10 months.
e Other parameters standard with 5% duty cycle (on/off, 30/600 s) except for patient on rapid cycle for 2 years (duty cycle > 50%).
98 K. Vonck et al.VNS also provides beneficial side effects such as
an antidepressant activity, mood improvement,
enhancement of recognition memory and reduced
daytime sleepiness in epilepsy patients.5,23,24 These
effects should also be taken into account when
generator replacement becomes an issue. Even in
patients in whom VNS does not have a clear anti-
epileptic effect but a positive influence on mood
and behaviour, generator replacement should be
seriously considered.
In non-responders, it seems acceptable to assess
changes in seizure frequency during the months
following EOES. It should be taken into account
however that if seizure frequency increases, it
may not always be possible to easily regain control
using the same stimulation parameters. Currently,
the number of patients we have described is too
small to identify any predicting factors for not
regaining previous seizure control.
Ramping-up of the output current seems to
become more difficult with an increasing time
delay between EOBL and generator replacement.
Two of our patients did not tolerate previously
well-tolerated output current values. This finding
was recently reported by Ponticello et al.25 espe-
cially in patients with higher pre-reimplant cur-
rent settings and also by Tatum et al.9 It has been
hypothesized that stimulator output current
diminishes during the time between EOES and
EOBL, resulting in stimulation with lower output
currents during a variable period of time.25 When
generator replacement is performed before any
signs of battery depletion appear, output current
can usually be reinstalled immediately. Also
the effect of a greater stimulus strength provided
by the newer generator models has been
proposed.9
On the basis of the detailed evaluation of our
initial patients, we try to follow a clinically and
economically plausible strategy for future generator
replacement in a larger patient group. The magnet
provides a useful feature to predict EOES in some
patients, but cannot be relied on exclusively. The
follow-up frequency of patients is increased a few
months before the time of earliest expected battery
failure has been reached. Specifically, seizure-free
patients or patients that respond well to VNS are
encouraged to increase the frequency of their fol-
low-up visits. Generator replacement in these
patients is planned before any signs of EOES are
present, to avoid the risk of recurrent seizures or
losing other beneficial side effects such as mood
improvement. Especially in patients who carry a
model 100 without the ERI feature this might be
done weeks to months before the earliest expected
EOES.In non-responders, generator replacement is a
more controversial issue. The preferred strategy
could be to postpone replacement in order to eval-
uate possible changes in seizure frequency during
several weeks following EOBL. Based on this assess-
ment the decision to replace or remove the device
can be made. The decision should take into account
that regaining pre-replacement seizure reduction,
even when that reduction was modest, is not always
possible.Conclusion
In patients treated with VNS, seizure control can be
lost acutely or gradually following EOES or EOBL.
From this report, it appears that once seizure con-
trol is lost, it cannot always be regained after gen-
erator replacement. In order to prevent this
avoidable risk, an effort should be made to estimate
battery life in individual patients. Defining and
predicting the exact time of occurrence of EOES
proves difficult. From our initial experience in this
small group of patients, we suggest to perform
generator replacement in responders at the time
corresponding to the shortest predicted battery life
before EOES or EOBL is reached. In patients with
high output currents (>2 mA) and/or relatively high
lead impedance values (>3 kV) and/or high duty
cycles the time period between EOES or ERI notifi-
cation and EOBL is expected to be short. In non-
responders, delaying the decision to replace the
generator might be a reasonable option. Frequent
follow-up of these patients to monitor changes in
seizure frequency and severity, and to determine
whether any other beneficial effects of VNS have
been lost, may help to establish the need for gen-
erator replacement. Also, in these patients, the
time interval between EOES and/or ERI notification
and EOBL should be monitored to guide the timing of
future generator replacements in these and other
patients. From these initial observations, we hope
to encourage prospective collection of data on gen-
erator replacement in larger patient groups includ-
ing children. This may allow meaningful statistical
analysis and formulation of specific guidelines on
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